A video podcast by the American Society for Microbiology that highlights the latest in microbiology, life science and biotechnology news. ASM is composed of over 42,000 scientists and health professionals with the mission to advance the microbial sciences as a vehicle for understanding life processes and to apply and communicate this knowledge for the improvement of health and environmental and economic well-being worldwide. For information about ASM and MicrobeWorld, visit us online at www.microbeworld.org. For questions and/or feedback please email firstname.lastname@example.org.
Anna Kavanaugh hosts the weekly radio series, "Mad Science: The Genetic Crossroad." The program aims to raise awareness and provide education about genetically modified organisms (GMO), in the world food supply and the practices of the GM biotech industry. The series is dedicated to all issues surrounding GM foods, its usage and ramifications thereof. Anna is a writer, advocate, and founder of the (AKCF) Anna Kavanaugh Charitable Foundation. Her original novel, "The Cord of Callows," now an upcoming expanded trilogy series, is the inspiration for a GMO documentary film entitled, "The Cord of Callows trilogy: Fact Behind the Fiction. Fear Behind the Fact."
Filmed live at ASM Biodefense 2016 with special guests: Rebekah Kading and Wyndham Lathem. From the ASM Biodefense and Emerging Diseases Research meeting, Vincent Racaniello speaks with Rebekah and Wyndham about their work on Rift Valley Fever virus and other vector-borne pathogens, and the evolution and pathogenesis of Yersinia pestis, the agent of plague. See the video version at microbeworld.org/mwv
By email@example.com (American Society for Microbiology)
About 1.3 million people in the United States have type 1 diabetes, which requires constant monitoring and regular injections of insulin. The autoimmune disease attacks the insulin producing beta cells in the pancreas and replacement of those cells has long been viewed as an ideal approach to treating the disease. The problem, though, has been finding a reliable supply or replacement cells and protecting them from the body’s immune system while allowing them to recieve needed nutrients, as well as deliver insulin to the body. San Diego-based ViaCyte is now in human clinical trials with a promising approach to treating the disease. We spoke to Paul Laikind, president and CEO of ViaCyte, about the company’s cell therapy, its critical financial support from the California Institute for Regenerative Medicine and JDRF, and why its investigational product may represent a functional cure.
Non-steroidal anti-inflammatory drugs are the most widely used medications in the world. They are used to treat pain resulting from diseases such as arthritis, but these drugs can raise blood pressure and cause serious problems including heart attacks, strokes, and death. We spoke to Paul Waymack, founder, chairman, and chief medical officer of Kitov Pharmaceuticals about its efforts to bring to market a combination therapy that addresses these safety concerns. Waymack discussed the issues surrounding pain medications, his company’s approach, and how the company’s smart FDA strategy is significantly cutting its cost and time to market.
Ralph Minter of MedImmune will describe his approach for phenotypic antibody screening and how it is being used to discover both novel antibodies and targets. He will discuss tips for overcoming obstacles to identifying novel targets, share advice for getting best results with phenotypic screening and describe how this work has been impacted by recent discoveries in the tumor microenvironment. For more information, please visit http://www.PEGSummit.com/
CHI recently interviewed Dr. Dmitry Samarsky, Senior Vice President of Technology and Global Business Development at OliX Pharmaceuticals, regarding the evolution of nucleic acid-based therapeutics; challenges within this space; recent advances in chemistry and delivery; and the greatest opportunities within this space over the next few years. Discussion questions include: 1 Given the obvious benefit of oligonucleotide therapies being able to dramatically expand target space, why haven’t they impacted the drug development landscape as much as Biologics or small Molecules? What challenges have been encountered within this field? 2 It seems as if there has be a resurgence of interest in the discovery and development of oligonucleotide therapeutics. Why do you think this is? What has changed over the past few years? 3 You are hosting a workshop during the upcoming Oligonucleotide Therapeutics and Delivery conference, providing an overview of oligonucleotide therapeutics from discovery ...
Romney Humphries, Assistant Professor, UCLA Pathology & Laboratory Medicine, Section Chief of Clinical Microbiology, David Geffen School of Medicine, University of California, Los Angeles spoke to CHI to discuss how Next-Generation Sequencing has changed the way scientists detect antimicrobial resistance as well as the challenges scienctists face moving forward. Dr. Humprhies is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the Molecular Medicine TriConference. For details, visit http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/
Why are obesity, juvenile diabetes and asthma increasing? Is it something in the environment or in our modern lifestyle? Dr. Martin Blaser thinks that it may be due to changes in our microbiome – the ecosystem of tiny microscopic creatures that live in and on us. Learn about his hypothesis that some of the greatest medical advances in the 20th century – antibiotics, C-sections and antiseptics- may be having unintended consequences. Dr. Martin Blaser has studied the role of bacteria in human disease for over 30 years. He is the director of the Human Microbiome Program at NYU. He founded the Bellevue Literary Review and has been written about in newspapers including The New Yorker, Nature, Science, The New York Times, The Washington Post, and The Wall Street Journal. His more than 100 media appearances include The Today Show, The Daily Show, Fresh Air (NPR) GMA, the BBC, The O'Reilly Factor, and CNN. He lives in New York City.
By firstname.lastname@example.org (American Society for Microbiology)
The American Association for Cancer Research, with seven leading cancer research centers, has launched Project GENIE to determine how to better tailor treatments to patients’ individual cancers. The effort will take tumor genomic profiling data from the various institutions and aggregate it into a single database for researchers to harness. We spoke to Barrett Rollins, chief scientific officer at the Dana-Farber Cancer Institute, about the project, how far down the path of precision medicine we have travelled, and how he expects it to reshape cancer care in the years to come.
As medical device makers are building network connectivity and intelligence into their products, they are adding new vulnerabilities and risks as well. The U.S. Food and Drug Administration has just issued draft guidance for postmarket management of cybersecurity of medical devices. It follows previous guidance on premarket submissions for management of cybersecurity in medical devices. We spoke to Russell Jones, partner with Deloitte & Touche, cyber risk leader for the firm’s State of California Practice and co-leader of the firm’s medical device safety and security practice, about the FDA actions, how these connected devices can be exploited by hackers, and what medical device makers can learn from industries that have already faced these issues.
Alright everyone, here is Episode 62, “Forever Young” featuring Dr. Aubrey de Grey. This and all of our episodes are sponsored by Thermo-Fisher Scientific. Go to stemcellpodcast.com for all of our episodes and to sign up for our newsletter. We begin as always with the Science Round Up, sponsored by Biotechne and discuss the latest science/stem cell news including: differences in males and females stress susceptibility key elements of healthy eating habits a new marker of stem cells in the ovaries engineered stem cells may help in ALS how squeezing cells can help reprogramming efficiency For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on writer, and researcher Dr. Aubrey de Grey to discuss his work on anti-aging. We talk with Dr. de Grey on his latest findings and his ultimate goal of eliminating aging so we call can one day celebrate our 1000th birthday. After this, there is a rant about how ridiculous cable bills are. This will be our last episo ...
The pharmaceutical industry appears to have lost ground in 2015 on the ongoing debate around drug pricing, a problem that Christopher Bowe sees in part as a failure of leadership within the industry. In a recent guest column in Forbes, Bowe, who advises industry CEOs on communicating their strategies and ideas, argued that the industry needs CEOs capable of reframing the discussion with fresh ideas, forging new alliances, and disrupting existing business models. We spoke to Bowe about this leadership vacuum, why it is critical for the industry to move beyond its tired arguments, and what it needs to do to rebuild trust and credibility with the public.
CHI speaks with Dr. Klaus Pantel, a professor and founding director of the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf in Germany. In this podcast Dr. Pantel discusses the steps needed to make liquid biopsy the standard-of-care, its most promising applications, and future directions. Dr. Pantel also adds his voice to the debate over whether or not early detection is viable, and in which indications it may make the most sense. For more information, please visit http://www.MolecularDXEurope.com/
CHI chats with Dr. Raymond J. Langley, Assistant Professor, Department of Pharmacology, University of South Alabama. Dr. Langley discusses the latest research and developments in metabolomics risk analysis models for sepsis and predictive biomarkers for patient survival, as well as the current challenges in developing technology for metabolomics diagnostics for sepsis. Dr. Langley is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the . For details, visit http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/
As 2015 came to a close, Congress passed a package of tax extenders that among other things expanded the Research and Development Tax Credit and made it permanent. The move represents a big win for innovation-based industries, but the life sciences in particular, which will benefit from a new provision that allows companies to capitalize on the credit ahead of producing revenue. We spoke to Dan Mennel, California Market Leader of Strategic Federal Tax Services for Grant Thorton and Matt Gardner, CEO of the California Technology Council, about the R&D tax credit, what it does, and what it means for the life sciences.
Happy New Year everyone, thanks for all the support in 2015 and looking forward to a great 2016. The Stem Cell Podcast is presented by Thermo-Fisher Scientific, please go to stemcellpodcast.com for all our episodes and to sign up for our newsletter. In this episode we start with our signature science roundup, a quickie but goodie. Some of the papers we discuss include: New elements added to the periodic table Stem cells to save the endangered white rhino species A new way to make serotonin neurons Human stem cells injected into a mouse embryo Stem cells can make cells that help functionally recover a model of spinal cord injury. For the interview portion of the show sponsored by STEMCELL Technologies, we feature some of our conversations with attendees from the 2015 World Stem Cell Summit from Atlanta, GA. Finally we close with a rant on noisy radiators and how heat dries out your nose. Happy New Year! Below are all of the papers mentioned on the show. We are working on a way to ca ...
The year 2015 was another big one for biotech with record dealmaking, big drug approvals, and solid performance, but it somehow didn’t feel as good as it looks on paper. Pricing concerns that garnered big attention are expected to grow in intensity in the new year with the presidential election and negotiations for the renewal of the Prescription Drug User Fee Act. We spoke to Adam Feuerstein, senior columnist for TheStreet.com, about the year in biotech, the highs and lows, and what’s ahead in the new year.
CHI chats with Bert Smeets, Ph.D., Professor, Clinical Genomics, Mitochondrial Diseases, Maastricht University Medical Center. Dr. Smeets discusses the latest research and developments on diagnosing mtDNA disease using Next-Generation Sequencing, as well as his work in developing techniques to prevent mtDNA disease transmission and developing therapeutics for those affected by mtDNA disease. Dr. Smeets is one of our speakers for the Novel Diagnostic Approaches session at the Reproductive Genetic Diagnostics conference, 6-7 April, in Lisbon. For details, visit http://www.MolecularDXEurope.com/Reproductive-Genetic-DX
Growing costs pressures, the integration of technology, and the transformation of the patient into a healthcare consumer is giving rise to a new health economy. In its report on the top health industry issue for 2016, PwC highlights the forces expected to have the most impact on the industry in the coming year. We spoke to Karla Anderson, principal of U.S. pharmaceuticals and life sciences for PwC, about the report, how an increasing emphasis on value is reshaping the sector, and what’s in store for 2016.
Nature Biotechnology talked to Wilson about his love of motocross racing, the triumphs and tribulation of gene therapy (including the Jesse Gelsinger tragedy), and the future of drug pricing.
By email@example.com (Nature Biotechnology)
First off thank you everyone for listening to us in 2015, we had a really great year and excited for what’s to come in 2016! Our current show is Episode 60, “Stemcentrx” ft. Dr. Scott Dylla. The Stem Cell Podcast is presented by Thermo-Fisher Scientific, please go to stemcellpodcast.com for all our episodes and to sign up for our newsletter. In this episode we do not do a traditional science round but instead review some of the talks that can be found on the 24 Hour of Stem Cell event put on by Thermo-Fisher. Some of these talks include: Bio-materials for stem cells and organoids Activity of neurons firing in a dish Tissue engineering for cardiac repair Modeling predisposition to schizophrenia using iPS cells shRNA screens identify regulators of stem cell self-renewal. For our interview we bring on Scott Dylla, CSO and co-founder of Stemcentrx a really cool new company that is using novel technology to target stem cells as a therapy for different cancers. Finally we close out the y ...
Despite a record number of new drug approvals this year, the return on R&D investment for the largest pharmaceutical companies continues to fall, according to a new report from the Deloitte Centre for Health Solutions and Deloitte’s R&D services group. In fact, the report finds R&D returns for this group of companies have fallen to their lowest point since Deloitte began tracking them in 2010. We spoke to Neil Lesser, principal with Deloitte Consulting in the Life Sciences strategy practice and a leader in the Research & Development strategy practice, about the report, the pressures on the industry that are hurting returns, and what R&D strategies companies can pursue that might reverse the trend.
Peter Luppa of the Technishe Universität in München will outline what he considers some of the greatest obstacles to implementing POC testing in the clinical setting and describe the need for quality standards. He will share advice for introducing POCT within the clinical setting and some of the most exciting applications emerging for POC and how they fit into the theranostic/health monitoring ecosystem.
Retail prices for more than 100 widely used specialty drugs rose nearly 11 percent in 2013, according to a new report from AARP Public Policy Institute. The report found that the average annual cost of a specialty drugs used to treat chronic diseases rose to more than $53,000 — greater than the U.S. median income and more than twice the $23,500 median income of people on Medicare. We spoke to Leigh Purvis, director of health services research in AARP’s Public Policy Institute about the report, trends that are fueling demand for these drugs, and whether there are public policy solutions to rein in rising drug prices that can be implemented without harm to innovation.
Thanks for tuning in for Episode 59 of The Stem Cell Podcast, “Clinical Grade” featuring Dr. Tilo Kunath. This and all of our episodes are presented by Thermo-Fisher Scientific. Go to stemcellpodcast.com for all of our episodes and to sign up for the newsletter. We begin as always with the Science Round Up and discuss the latest science and stem cell news including: A way to grow stem cells on seaweed A meeting describing the state of disease modeling using stem cells Sleep derivation affects stem cell transplants Cranberry juice just as effective as antibiotic for urinary tract infections Smoking really strong weed strains can affect your brain A new way to make retinal cells from stem cells For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on researcher Dr. Tilo Kunath to discuss his work on characterizing clinical grade stem cells so they can be used for patient therapies. We talk to Tilo about his past and current work including his latest pape ...
A team of biohackers is developing the first open source protocol to produce insulin simply and economically. The hope is that their work will serve as the basis for generic production of insulin and provide a foundation for continued research into improved versions of the life saving biologic. We spoke to Anthony Di Franco, co-founder of the Open Insulin project and a board member of Counter Culture Labs, about the work, the challenges they are encountering, and whether the DIY movement can teach the corporate world anything about cost-effective innovation.
Dr. Ian Hunt of Novartis speaks to CHI on December 1, 2015. Dr. Hunt will be presenting during the Applying Expression Platforms conference at 2016’s PepTalk, January 18-22 in San Diego, California. Topics include development of high-throughput protein technologies and different strategies to make more difficult proteins, the recent explosion in technologies to solve X-ray crystallography of GPCRs, applying such technologies into the drug discovery context, generation of very large protein complexes and more. Find more information at http://www.CHI-PepTalk.com/
A large number of clinical trials underlying the approval of drugs never come into public view. This not only has legal and ethical ramifications, but implications for the healthcare system as a whole. We spoke to Jennifer Miller, founding president of Bioethics International and assistant professor at the NYU School of Medicine about her recent study in BMJ Open, part of an effort to improve transparency through the creation of a Good Pharma Scorecard. Miller discussed the study, the scorecard, and the state of transparency in the pharmaceutical industry.
Thanks for tuning in for Episode 58, “Heart Disease Modeling” featuring Dr. Lior Gepstein. This and all of our episodes are sponsored by Thermo-Fisher Scientific. Go to stemcellpodcast.com for all of our episodes and to sign up for the newsletter. We begin as always with the Science Round Up and discuss the latest science/stem cell news including: Discovery of a new STD. Stem cells generated from urine used to help discover new drugs for cholesterol disease? A new stem cell method to model diseases of the muscle. A stem cell company bought out for 380 million dollars. Impaired sense of smell may indicate dementia. More NFL stars going for stem cell therapies. For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on clinician and researcher Dr. Lior Gepstein to discuss his work on using stem cells to model heart disease. We talk to Dr. Gepstein about his past and current work including his latest paper published in Stem Cell Reports. Finally we close th ...
Vincent take This Week in Microbiology to the University of California, San Diego campus and into the the laboratories of Kit and Joseph Pogliano, where he learns about their work on the bacterial cytoskeleton, sporulation, and the effects of antibiotics on bacterial cells.
By firstname.lastname@example.org (American Society for Microbiology)
The power of genetic engineering will soon be available for the home thanks to the Amino One, a piece of hardware about the size of a laptop computer that would allow users to manipulate the DNA of microorganisms for productive purposes or just plain fun. We spoke to Julie Legault, founder and CEO of Amino One’s creator Amino Labs, about the device, its target market, and the implications of putting the tools of synthetic biology into the hands of kids.
New gene editing technologies are expanding the ease and power with which scientists can manipulate biological systems with the promising of addressing not only human health issues, but problems the plant faces with regards to food, fuel, and the environment. But while much of the concerns raised about the potential consequences of this technology have focused on its use in humans, Elizabeth Alter, assistant professor of biology at City University of New York’s York College, argues its potential environmental implications will likely be far more significant. We spoke to Alter about her recent op-ed in The New York Times, the need for public discussion about the technology, what should be done today as we work through broader questions of policy.
Mad Science: The Genetic Crossroad With Anna Kavanaugh
One of the latest practices in biotech is a process that allows DNA to be edited down to the letter. Known as CRISPR technology, scientists now have the ability to control gene mechanisms with unprecedented accuracy and without traditional invasive high-cost GMO procedures as they exist now. In effect, CRISPR is the evolution of GMO. All of this allows corporations to continue producing genetically altered foods without ever having to worry about legislation or labeling mandates. As consumer "right to know" demand increases and more companies are responding to protests by voluntarily labeling GMO products or removing them from their ingredients altogether, industry is well ahead of the game and consumers should not be fooled into complacency. CRISPR technology allows a crafty bypass because it is not recognized technically as a GMO process as is currently defined. Industry can use this technology to dodge existing regulations now, or in the future, and avoid GMO stigmas in public p ...
Thanks for tuning in for Episode 57, “Curiosity” featuring Duane Fernandez. This and all of our episodes are sponsored by Thermo-Fisher Scientific. Go to stemcellpodcast.com for all of our episodes and to sign up for the newsletter. We begin as always with the Science Round Up and discuss the latest science/stem cell news including: A woman that can smell Parkinson’s disease? Will we ever be able to treat female infertility with stem cells? A new gene that regulates the stem cell number A new stem cell model of bi-polar disorder A common allergy medication might help your brain For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on writer, director and photographer Duane Fernandez to talk about how curiosity drives him and his work. We talk to Duane on his experience with helping people from all walks of life and business experience their true potential and how this can apply to science. Finally we close the show with our signature rant on labeling t ...
Vincent, Elio, and Michele meet with Harry Mobley, Mary O’Riordan, and Vince Young at the University of Michigan, during the designation of the Department of Microbiology and Immunology as a Milestones in Microbiology site. They discuss how the laboratory has advanced the science and teaching of microbiology, and discuss faculty work on uropathogenic E. coli, induction of stress by bacterial infection, and the gut microbiome.
By email@example.com (American Society for Microbiology)
The U.S. Securities and Exchange Commission last week finalized rules on crowdfunding that opens the door for the participation of non-accredited investors. The rules complete a long process for the commission set into motion by the passage of the JOBS Act. We spoke to Richard Swart, director of research for the Program for Innovation in Entrepreneurial and Social Finance at the University of California at Berkeley and chief strategy officer for the crowdfunding investment site NextGen Crowdfunding, about the new rules, how this will change the investment landscape, and what it all means for the biotech industry.
Mad Science: The Genetic Crossroad With Anna Kavanaugh
Throughout the GMO, biotech and agrochemical debates, we have witnessed the ultimate in corporate control and influence along with the disastrous impacts from the implementation of these technologies in our world food supply, pharmaceuticals, and the reckless tampering of DNA for profit-driven purposes. These impacts pose drastic effects to our human health and evolutionary process in a variety of ways. However, there is another critical aspect to the larger picture of which we are not talking enough about: the frightening consequences resulting from the biotech industry that now compromise the delicate balance of our planetary ecology and environment. As the hand of biotech continues to sweep across and outright ignore all reasonable boundaries of ethics and morality in its unquenchable thirst for power and profit, how close are we to the final curtain-call where nature, in its own inevitable wisdom, will protest against us and what cost will future generations have to pay for the ...
Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI on October 30. Both Peter and Pepper will be speaking at CHI’s Third Annual Advances in Prenatal Molecular Diagnostics conference, taking place in Boston on November 16-18. Topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider. Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed. For more information, visit http://www.HealthTech.com/Prenatal-Diagnostics/
Growing challenges in the areas of health, food, energy, and the environment have increased efforts to harness biology to create sustainable solutions to global problems. With advances in the ability to engineer microbes to perform desired tasks, the rapidly evolving area of synthetic biology is expected to fundamentally reshape industrial processes and give rise to a new bioeconomy. Leading scientists, entrepreneurs, and investors will gather in San Francisco November 4 through 6 for SynBioBeta SF 2015 to explore the state of synthetic biology. We spoke to Richard Kitney, professor of biomedical systems engineering at Imperial College London and one of the leading scientists behind the United Kingdom’s efforts in synthetic biology, about the upcoming conference, where the state of the science is today, and why scaling up to industrial sized processes remains a big challenge.
Thanks for tuning in to Episode 56, Glia featuring Dr. Steven Goldman. This and all of our episodes are sponsored by Thermo-Fisher Scientific. Go to stemcellpodcast.com for all of our episodes and to sign up for our newsletter. We begin as always with the #SciRoundUp and discuss the latest science and stem cell news including: Diamonds can detect cancer? A vaccine for AIDS brought to the clinic An “in womb” stem cell trial to begin? Stem cell burgers coming soon Stem cells to alleviate dementia For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on stem cell expert Dr. Steven Goldman from the University of Rochester to talk about glial cells and his work using stem cells to model and fix diseases like Multiple Sclerosis using Neural Stem Cells. Finally, we close the show with our signature rant on: “when someone tells you, you look tired.” Enjoy! Below are all of the papers mentioned on the show. We are working on a way to categorize all of the resea ...
Watch the pilot episode of BioFilms in which we explore some creepy microbes just in time for Halloween. Learn how algae can suffocate a pond of all its life, discover the vampire bacterium known as Vampirococcus who literally sucks the life out its victims, and watch out for those sweet Halloween treats that can leave holes in your teeth!
By firstname.lastname@example.org (American Society for Microbiology)
Vincent meets up with Romney and Duncan at the 79th annual meeting of the Southern California branch of the American Society for Microbiology, where they talk about emerging technologies for antimicrobial susceptibility testing, and next generation sequencing and advanced molecular diagnostics. Visit microbeworld.org/twim for complete shownotes including links mentioned.
By email@example.com (American Society for Microbiology)
A new class of immunotherapies is promising to radically alter the treatment of cancers and has generated excitement among investors for their groundbreaking potential. Now the Loncar Cancer Immunotherapy ETF provides a way for investors to bet on the sector through an exchange traded fund that consists of both Big Pharma and emerging growth biotechs leading the sector. We spoke to Brad Loncar, CEO of Loncar Investments and creator of the ETF, about the fund, why the focus on this narrow slice of the biotech world, and why he thinks immunotherapies will dramatically reshape cancer care in the years ahead.
Wall Street doesn’t like uncertainty and there are a number of policy issues now brewing that threaten to create some uncertainty for the biotechnology industry. As the BIO Investor Forum kicks off in San Francisco October 20 and 21, bringing together investors and CEOs for two days of panels and presentations, the conference will turn its attention to policy issues and the effects they have on valuations within this industry. We spoke to Sara Radcliffe, president and CEO of the California Life Sciences Association and a policy panelist and the BIO Investor Forum, about policy issues the industry faces, the growing controversy over pricing, and what policy matters investors should be watching.
Happy Stem Cell Awareness Day SCP fans and welcome to Episode 55. Be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin this episode by answering some questions from you the audience, thank you to everyone that submitted their questions and apologies to those that we could not get to. After this we do a mini-Science Roundup sponsored by Thermo Fisher including: Creation of rudimentary kidneys from stem cells A new method to generate “old” neurons A new company created to create genetically modified pigs Flowing water found on Mars For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on Dr. David Mooney, Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences to discuss his work using Biomaterials to help stem cells more efficiently integrate after transplantation. We then finish off the show with a rant on automatic flushing toilets. Enjoy! Below are all of the pape ...
The medtech industry has enjoyed robust M&A activity, strong financings, and a rise in R&D investments, but other numbers point to troubling developments that threaten the future health and growth of the industry, according to a new report from EY. We spoke to Ellen Licking, EY Life Sciences lead analyst, about the report, concerns about the venture capital industry’s move away from the sector, and questions about who will fund early-stage innovation that will be necessary for the future growth of the industry.
Vtesse, a rare disease drug development company, this week announced that it was initiating a late-stage pivotal trial for its lead experimental therapeutic to treat Niemann-Pick Type C1 disease. The start of the trial for the nine month old company represents a major milestone and suggest its history with the National Institutes of Health and the rare disease drug accelerator Cydan Development may point to new ways of cutting the time and cost of advancing a drug to market. We spoke to Ben Machielse, CEO of Vtesse, about the rapid pace at which the company has been able to move, the role NIH has played, and whether this points to new ways to accelerate the drug development process.
Welcome everyone to Episode 54. Be sure to visit stemcellpodcast.com for current and past episodes and to sign up for our newsletter. We begin as always with our Science Roundup sponsored by Thermo Fisher. In this episode, we discuss topics ranging from: A new type of cells called calendar cells STAP cells finally put to bed An amazing visualization of the bone marrow stem cell niche A new CRISPR enzyme discovered Standing up and getting dizzy might mean bad things for you down the line GMP stem cell manufacturing Predictions for the Nobel prize awards announced next week A new drug for Alzheimer’s And much more… For the interview portion of the show, sponsored by STEMCELL Technologies, we bring on Dr. Andrew Cohen, Associate Professor at Drexel University, to discuss his work on creating new software and programs to track stem cell lineages using time lapse video data. We then finish off the show with a rant on “double dipping.” Enjoy! Below are all of the papers mentioned on the ...
CHI chats with Rebekah S. Zimmerman, Ph.D., FACMG, Director, Clinical Genetics, Foundation for Embryonic Competence. Dr. Zimmerman discuss the latest technologies she and her non-profit lab are working with and developing, including how the non-profit lab is different from a typical PGD lab. Dr. Zimmerman is one of our speakers for the Advances in NGS and Other Technologies session at the Reproductive Genetic Diagnostics conference. For details, visit http://www.Healthtech.com/Reproductive-Genetic-Diagnostics
The U.S. Department of Health and Human Services has been working to move Medicare from fee-for-service to value-based payments. It’s seeking to get 90 percent of payments to being value-based by 2018. The problem, according to a recent Viewpoint in JAMA, is that when addressing life-ending chronic conditions faced by older patients, traditional professional standards that drive today’s metrics don’t effectively address patient desires. We spoke to Joanne Lynn, director of the Altarum Institute’s Center for Elder Care and Advanced Illness and lead author of the JAMA Viewpoint, about what value-based care means for patients near the end of their lives, the need to recognize the great variance in patient desires, and how healthcare systems will need to change to account for this.